Bliss GVS Pharma Limited
Financial trend (100/100) does the heavy lifting; valuation (54/100) is the drag.
Buy zoneBliss GVS Pharma Limited earns a Strong Buy from StocksWizard, with a blended score of 76/100. On 38.7x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 14% below its 52-week high of ₹538.55 and 266% above the low of ₹127.37. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. It clears 9 of 13 investability checks, with durability 70, valuation 61 and momentum 92 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹364.03.
1-year price
EOD · 2026-07-3152-week range
-13.54% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy76Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 11.6%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 30%
- Pass: Earnings growing: 125%
- Pass: Net margin ≥ 10%: 13.9%
- Pass: Current ratio > 1.5: 4.02
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 13.55
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Shareholding
- Promoter57.5%
- Institutions6.7%
- Public & other35.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 13.55.
Opportunities
- Earnings growing (125% YoY).
- Revenue growing (30% YoY).
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Weak Piotroski score (3/9).
About Bliss GVS Pharma Limited
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations across India and internationally. The company produces drugs across multiple therapeutic categories including anti-diabetic, anti-infective, anti-inflammatory, antifungal, cardiovascular, dermatological, gastrointestinal, neurological, ophthalmic, respiratory, and urological products, along with over-the-counter medications and supplements. It also provides pain management services and engages in pharmaceutical exports.
Bliss GVS Pharma Limited — frequently asked questions
Is Bliss GVS Pharma Limited a buy, hold or sell?
StocksWizard currently rates Bliss GVS Pharma Limited (BLISSGVS) a Strong Buy, based on a blended score of 76/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Bliss GVS Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Bliss GVS Pharma Limited's fair value at about ₹455.03, versus a current price of ₹465.65 — roughly 2% downside. On that basis the stock looks fairly valued.
Is Bliss GVS Pharma Limited financially healthy?
Bliss GVS Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Bliss GVS Pharma Limited's share price performed?
Bliss GVS Pharma Limited is up 73% over three months, and last traded at ₹465.65. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.